Recent developments in drug therapy for multiple sclerosis

Abstract

Symptomatic treatment of multiple sclerosis (MS) includes a diverse range of drugs intended to relieve the specific symptoms with which a patient may present at a particular point in the progression of the disease. These drugs, not specifically designed for the treatment of MS, may include antispastic agents (e.g. baclofen), drugs to reduce tremor (e.g. clonazepam), anticholinergics (e.g. oxybutynin) which relieve urinary symptoms, anti- epileptics (e.g. carbamazepine) to control neuralgia, stimulants to reduce fatigue (e.g. amantadine), and antidepressants (e.g. fluoxetine) to treat depression. The treatment of acute relapses or exacerbations is dominated by corticosteroids such as methylprednisolone. The most active area of current investigation is the development of drugs which will inhibit the progression of the disease process itself, and in this category the beta- and alpha-interferons are the most effective drugs currently available, although many new treatments are currently in trials, including immunoglobulin, copolymer-1, bovine myelin, T-cell receptor (TCR) peptide vaccines, platelet-activating factor (PAF) antagonists, matrix metallo-proteinase inhibitors, campath-1, and insulin-like growth factor (IGF).

Keywords

multiple sclerosis drug therapy beta-interferon

Get full access to this article

View all access options for this article.

References

Correale J , Rojany M , Weiner LP. (1997) Human CD8(+) TCR-alpha-beta(+) and TCR-gamma-delta(+) cells modulate autologous autoreactive neuroantigen-specific CD4(+) T-cells by different mechanisms . JNeuroimmunol 80: 47-64 .

Andersson P-B , Waubant E , Goodkin DE. (1997) How should we proceed with disease-modifying treatments for multiple sclerosis? Lancet 349: 586-587 .

Weinstock-Guttman B , Ranshoff RM , Kinkel P et al. (1995) The interferons: Biological effects, mechanisms of action, and use in multiple sclerosis . Ann Neurol 37: 7-15 .

van Oosten BW , Tragent L , Barkhof F et al. (1995) Multiple sclerosis therapy. A practical guide . Drugs 49: 200-212 .

Schluep M , Bogousslavsky J. (1997) Emerging treatments in multiple sclerosis . Eur Neurol 38: 216-221 .

Khoury SJ , Weiner HL. (1991) Therapy of multiple sclerosis, with particular reference to recent clinical trials . Curr Opinion Neurol Neurosurg 4: 191-195 .

Weinshenker BG , Sibley WA. (1992) Natural history and treatment of multiple sclerosis . Curr Opinion Neurol Neurosurg 5: 203-211 .

Heard RNS. (1993) New horizons in the treatment of multiple sclerosis . Med J Aust 158: 714-716 .

Bansil S , Cook SD , Rohowsky-Kochan C. (1995) Multiple sclerosis: Immune mechanism and update on current therapies . Ann Neurol 37 (S1): S87-S101 .

10.

Rudick RA et al. (1997) Management of multiple sclerosis . New Engl J Med 337: 1604-1611 .

11.

Dressnandt J , Conrad B. (1996) Lasting reduction of severe spasticity after ending chronic treatment with intrathecal baclofen . J Neurol Neurosurg Psychiat 60: 168-173 .

12.

Nance PW , Sheremata WA , Lynch SG et al. (1997) Relationship of the antispasticity effects of tizanidine to plasma concentration in patients with multiple sclerosis . Arch Neurol 54: 731-736 .

13.

Wagstaff AJ , Bryson HM. (1997) Tizanidine - A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders . Drugs 53: 435-452 .

14.

Hauser SL , Doolittle TH , Lopez-Bresnahan M et al. (1992) An antispasticity effect of threonine in multiple sclerosis . Arch Neurol 49(9): 923-926 .

15.

Mueller ME , Gruenthal M , Olson WL et al. (1997) Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis . Arch Phys Med Rehabil 78: 521-524 .

16.

Upton N. (1994) Mechanisms of action of new anti-epileptic drugs: Rational design versus serendipitous findings . Trends Pharmacol Sci 15: 456-463 .

17.

Perucca E. (1996) The new generation of antiepileptic drugs: advantages and disadvantages . Brit J Clin Pharmacol 42: 531-543 .

18.

Brenneisen R , Egli A , Elsohly MA et al. (1996) The effect of orally and rectally administered delta-9-tetrahydrocannabinol on spasticity. A pilot study with two patients . Int J Clin Pharmacol Therap 34: 446-452 .

19.

Consroe P , Musty R , Rein J et al. (1997) The perceived effects of smoked cannabis on patients with multiple sclerosis . Eur Neurol 38: 44-48 .

20.

Bidaut-Russell M , Devane WA , Howlett AC. (1990) Cannabinoid receptors and modulation of cyclic AMP accumulation in the brain . J Neurochem 55: 21-27 .

21.

Mackie K , Lai Y , Westenbroek R et al. (1995) Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor . J Neurosci 15: 6552-6563 .

22.

Smith PF , Darlington CL. (1996) Cannabis. Uses and abuses . New Ethicals. May: 79-83 .

23.

Bever CT , Anderson PA , Leslie J et al. (1996) Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients - results of a randomized, double-blind, placebo-controlled crossover trial . Neurol 47: 1457-1462 .

24.

Schwid SR , Petrie MD , Modermott MP et al. (1997) Quantitative assessment of sustained release 4-amino-pyridine for symptomatic treatment of multiple sclerosis . Neurol 48: 817-821 .

25.

Clarke CE. (1997) Botulinum toxin type A in cerebellar tremor caused by multiple sclerosis . Eur J Neurol 4: 68-71 .

26.

Rice GPA , Lesaux J , Vandervoort P et al. (1997) Ondansetron, a 5HT3 antagonist, improves cerebellar tremor . J Neurol Neurosurg Psychiat 62: 282-284 .

27.

Stahl JS , Rottach KG , Averbuchheller L et al. (1996) A pilot study of gabapentin as treatment for acquired nystagmus . Neuro-Ophthamol 16: 107-113 .

28.

Starcke M , Albrecht H , Pollmann W et al. (1997) Drug therapy for acquired pendular nystagmus in multiple sclerosis . JNeurol 244: 9-16 .

29.

Valiquette G , Herbert J , Meadedalisera P. (1996) Desmopressin in the management of nocturia in patients with multiple sclerosis - a double-blind, crossover trial . Arch Neurol 53: 1270-1275 .

30.

Fredrikson S. (1996) Nasal spray desmopressin treatment of bladder dysfunction in patients with multiple sclerosis . Acta Neurol Scand 94: 31-34 .

31.

Deridder D , Chandiramani V , Dasgupta P et al. (1997) Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia -A dual center study with long-term follow-up . JUrol 158: 2087-2092 .

32.

Houtchens MK , Richert JR , Sami A et al. (1997) Open label gabapentin treatment for pain in multiple sclerosis . Multiple Sclerosis 3: 250-253 .

33.

Samkoff LM , Daras M , Tuchman AJ et al. (1997) Amelioration of refractory dysesthetic limb pain in multiple sclerosis by gabapentin . Neurol 49: 304-305 .

34.

Lunardi G , Leandi M , Albano C et al. (1997) Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia . Neurol 48: 1714-1717 .

35.

Plioplys AV , Plioplys S. (1997) Amantadine and L-carnitine treatment of chronic fatigue syndrome . Neuropsychobiol 35: 16-23 .

36.

Krupp LB , Coyle PK , Doscher C et al. (1995) Fatigue therapy in multiple sclerosis -Results of a double-blind, randomized, parallel trial of amantadine, pemo-line and placebo . Neurol 45: 1956-1961 .

37.

Sterling MJ , Kane M , Grace ND. (1996) Pemoline-induced autoimmune hepatitis . Am J Gastroenterol 91: 2233-2234 .

38.

Geisler MW , Sliwinski M , Coyle PK et al. (1996) The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis . Arch Neurol 53: 185-188 .

39.

Sadovnik AD , Eisen K , Ebers GC et al. (1991) Cause of death in patients attending multiple sclerosis clinics . Neurol 41: 1193-1196 .

40.

Marazziti D , Cassano GB. (1996) Valproic acid for panic disorder associated with multiple sclerosis . Am J Psychiat 153: 842-843 .

41.

Chong SA , Ko SM. (1997) Clozapine treatment of psychosis associated with multiple sclerosis . Can J Psychiat 42: 90-91 .

42.

Barnes D , Hughes RAC , Morris RW et al. (1997) Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis . Lancet 349: 902-906 .

43.

De Keyser J , Zwanikken C. (1997) Oral versus intravenous corticosteroids in acute relapses of multiple sclerosis . Lancet 349: 1696-1698 .

44.

Silberberg DH. (1993) Corticosteroids and optic neuritis . New Engl J Med 329: 1808-1810 .

45.

Beck RW , Cleary PA , Trobe JD et al. (1993) The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis . New Engl J Med 329: 1764-1769 .

46.

Levic Z , Micic D , Nikolic J et al. (1996) Short-term high dose steroid therapy does not affect the hypothalamic-pituitary-adrenal axis in relapsing multiple sclerosis patients - clinical assessment by the insulin tolerance test . J Endocrinol Invest 19: 30-34 .

47.

Smith DR , Balashov KE , Hafler DA et al. (1997) Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: Increased interleukin-4 production and associated eosinophilia . Ann Neurol 42: 313-318 .

48.

Vanderhoeven JH. (1996) Decline of muscle fibre conduction velocity during short-term high-dose methylprednisolone therapy . Muscle and Nerve 19: 100-102 .

49.

Crockard AD , Treacy MT , Droogan AG et al. (1996) Methylprednisolone attenuates interferon-beta induced expression of HLA-DR on monocytes . J Neuroimmunol 70: 29-35 .

50.

Gasperini C , Pozzilli C , Bastianello S et al. (1998) Effect of steroids on GD-enhancing lesions before and during recombinant beta-interferon 1A treatment in relapsingremitting multiple sclerosis . Neurol 50: 403-406 .

51.

Kaufman M. (1997) Treatment of multiple sclerosis with high-dose corticosteroids may prolong the prothrombin time to dangerous levels in patients taking warfarin . Multiple Sclerosis 3: 248-249 .

52.

Schwid SR , Goodman AD , Puzas JE et al. (1996) Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis . Arch Neurol 53: 753-757 .

53.

Weiner HL , Dau PC , Khatri BO et al. (1989) Double-blind study of true vs sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis . Neurol 39: 1143-1149 .

54.

Sorensen PS , Wanscher B , Szpirt W et al. (1996) Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity - A randomized single-masked cross-over pilot study . Neurol 46: 1620-1625 .

55.

British and Dutch Multiple Sclerosis Azathioprine Trial Group . (1988) Double-masked trial of azathioprine in multiple sclerosis . Lancet 2: 179-183 .

56.

Yudkin PL , Ellison GW , Ghezzi A et al. (1991) Overview of azathioprine treatment in multiple sclerosis . Lancet 338: 1051-1055 .

57.

Confavreux C , Saddier P , Grimaud J et al. (1996) Risk of cancer from azathioprine therapy in multiple sclerosis A case-control study . Neurol 46: 1607-1612 .

58.

Salmaggi A , Corsini E , Lamantia L et al. (1997) Immunological monitoring of azathioprine treatment in multiple sclerosis patients . JNeurol 244: 167-174 .

59.

Rudge P , Koetsier JC , Mertin J et al. (1989) Randomised double blind controlled trial of cyclosporine in multiple sclerosis . J Neurol Neurosurg Psychiat 52: 559-565 .

60.

Multiple Sclerosis Study Group . (1990) Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial . Ann Neurol 27: 591-605 .

61.

Zhao GJ , Redekop WK , Riddehough A et al. (1997) Clinical and magnetic resonance imaging changes correlate in a clinical trial monitoring cyclosporine therapy for multiple sclerosis . JNeuroimag 7: 1-7 .

62.

Kappos L , Patzold U , Dommasch D et al. (1988) Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis - results of the German multicenter study . Ann Neurol 23: 56-63 .

63.

Millefiorini E , Gasperini C , Pozzilli C et al. (1997) Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis - 24 month clinical and MRI outcome . JNeurol 244: 153-159 .

64.

Edan G , Miller D , Clanet M et al. (1997) Therapeutic effect of mitoxantrone combined with methylpredniso-lone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria . J Neurol Neurosurg Psychiat 62: 112-118 .

65.

Goodkin DE , Rudick RA , Vanderbrug Medendorp S et al. (1995) Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis . Ann Neurol 37: 3-40 .

66.

Goodkin DE , Rudick RA , Vanderbrug Medendorp S et al. (1996) Low-dose oral methotrexate in chronic progressive multiple sclerosis: Analyses of serial MRIs . Neurol 47: 1153-1157 .

67.

Whitaker JN , Mitchell GW , Cutter GR. (1995) Clinical outcomes and documentation of partial beneficial effects of immunotherapy for multiple sclerosis . Ann Neurol 37: 5-6 .

68.

Beutler E , Sipe JC , Romine JS et al. (1996) The treatment of chronic progressive multiple sclerosis with cladribine . Proc Natl Acad Sci USA 93: 1716-1720 .

69.

Beutler E , Sipe JC , Romine JS et al. (1996) Treatment of multiple sclerosis and other autoimmune diseases with cladribine . Sem Hematol 33 (suppl. 1): 45-52 .

70.

Goodwin J. (1996) High dose corticosteroids in the treatment of optic neuritis and prophylaxis of multiple sclerosis . Clin Immunotherap 6: 405-412 .

71.

Filipovic SR , Drulovic J , Stojsavljevic N et al. (1997) The effects of high-dose intravenous methylprednisolone on event-related potentials in patients with multiple sclerosis . J Neurol Sci 152: 147-153 .

72.

Gelati M , Corsini E , Dufour A et al. (1997) Reduced adhesion of PBMNCS in methylprednisolone-treated MS patients - preliminary results . Acta Neurol Scand 96: 283-292 .

73.

Pitzalis C , Sharrack B , Gray IA et al. (1997) Comparison of the effects of oral versus intravenous methylprednisolone regimens on peripheral blood T lymphocyte adhesion molecule expression. T cell subsets distribution and TNF alpha concentrations in multiple sclerosis . J Neuroimmunol 74: 62-68 .

74.

Rosenberg GA , Dencoff JE , Correa N et al. (1996) Effect of steroids on CSF metalloproteinases in multiple sclerosis - relation to blood brain barrier injury . Neurol 46: 1626-1632 .

75.

Kivisakk P , Tian W , Fredrikson S et al. (1997) Multiple sclerosis -myelin basic protein induced mRNA expression of proinflammatory cytokines in mono-nuclear cells is suppressed by interferon-beta-1b in vitro . Eur J Neurol 4: 460-467 .

76.

Buttini M , Mir A , Appel K et al. (1997) Lipopolysaccharide induces expression of tumour necrosis factor-alpha in rat brain - inhibition by methylprednisolone and by rolipram . Br J Pharmacol 122: 1483-1489 .

77.

Fazekas F , Deisenhammer F , Strasser-Fuchs S et al. (1997) Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsingremitting multiple sclerosis . Lancet 349: 589-593 .

78.

Fazekas F , Deisenhammer F , Strasser-Fuchs S et al. (1997) Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis - Further analyses of the Austrian immunoglobulin MS study . Multiple Sclerosis 3: 137-141 .

79.

Achiron A , Barak Y , Goren M et al. (1996) Intravenous immunoglobulin in multiple sclerosis - clinical and neuroradiological results and implications for possible mechanisms of action . Clin Exp Immunol 104 (suppl. 1): 67-70 .

80.

Sorensen PS , Wanscher B , Schreiber K et al. (1997) A double-blind cross-over trial of intravenous immunoglobulin G in multiple sclerosis - preliminary results . Multiple Sclerosis 3: 145-148 .

81.

Achiron A , Rotstein Z , Barak Y et al. (1997) Intravenous immunoglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis - The Israeli experience . Multiple Sclerosis 3: 142-144 .

82.

Dalakas MC. (1997) Intravenous immune globulin therapy for neurologic diseases . Ann Int Med 126: 721-730 .

83.

Rodriguez M , Miller DJ , Lennon VA. (1996) Immunoglobulins reactive with myelin basic protein promote CNS remyelination . Neurol 46: 538-545 .

84.

Poser CM. (1997) Intravenous immunoglobulin for multiple sclerosis . Lancet 349: 1177-1178 .

85.

Mansmann PT , Ong SH. (1997) Interferon content of intravenous immunoglobulin - variation between preparations . Ped Asthma Allerg Immunol 11: 137-139 .

86.

Tian WZ , Navikas V , Matusevicius D et al. (1998) Linomide (Roquinimex) affects the balance between pro- and anti-inflammatory cytokines in vitro in multiple sclerosis . Acta Neurologica Scand 98(2): 94-101 .

87.

Drescher KM , Riveraquinones C , Lucchinetti CF et al. (1998) Failure of treatment with linomide or oral myelin tolerization to ameliorate demyelination in a viral model of multiple sclerosis . J Neuroimmunol 88: 111-119 .

88.

Anderson O , Lycke J , Tollesson PO et al. (1996) Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis . Neurol 47: 895-900 .

89.

Karussis DM , Meiner Z , Lehmann D et al. (1996) Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: A double-blind, placebo-controlled pilot study with the monthly magnetic resonance imaging evaluation . Neurol 47: 341-346 .

90.

Lehmann D , Karussis D , Mizrachikoli AS et al. (1997) Inhibition of the progression of multiple sclerosis by linomide is associated with upregulation of CD4(+)/CD45RA(+) cells and downregulation of CD4(+)/CD45RO(+) cells . Clin Immunol Immunopathol 85: 202-209 .

91.

Hall GL , Compston A , Scolding NJ. (1997) Beta-interferon and multiple sclerosis . Trends in Neurosci 20: 63-67 .

92.

IFNB Multiple Sclerosis Study Group . (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multi-center, randomized, double-blind, placebo-controlled trial . Neurol 43: 655-661 .

93.

Paty DE , Li DKB , UBC MS/MRI Study Group et al. (1993) Interferon-beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multi-center, randomized, double-blind, placebo-controlled trial . Neurol 43: 662-667 .

94.

Poser CM. (1997) Misdiagnosis of multiple sclerosis and beta-interferon . Lancet 349: 1916-1916 .

95.

Munschauer FE , Kinkel RP. (1997) Managing side effects of interferon-beta in patients with relapsingremitting multiple sclerosis . Clin Therap 19: 883-893 .

96.

Stone LA , Frank JA , Albert PS et al. (1995) The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis . Ann Neurol 37: 611-619 .

97.

Jacobs LD , Cookfair DL , Rudick RA et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis . Ann Neurol 39: 285-294 .

98.

Sibley WA. (1996) Clinical efficacy of interferon beta-1b in multiple sclerosis - the US/Canadian multicentre trial evidence . Clin Immunotherap 5 (suppl. 1): 41-46 .

99.

Rudick RA , Goodkin DE , Jacobs LD et al. (1997) Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis . Neurol 49: 358-363 .

100.

Calabresi PA , Stone LA , Bash CN et al. (1997) Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI . Neurol 48: 1446-1448 .

101.

Pozzilli C , Bastianello S , Koudriavtseva T et al. (1996) Magnetic resonance imaging changes with recombinant human interferon-beta-1b - A short-term study in relapsing-remitting multiple sclerosis . J Neurol Neurosurg Psychiat 61: 251-258 .

102.

Li DKB , Paty DW , Koopmans RA et al. (1996) The effects of interferon beta-1b in multiple sclerosis as assessed by MRI . Clin Immunotherap 5 (suppl. 1): 47-54 .

103.

Simon JH , Jacobs LD , Campion M et al. (1998) Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis . Ann Neurol 43: 79-87 .

104.

Durelli L , Bongioanni MR , Cavalo R et al. (1994) Chronic systemic high dose recombinant interferon alpha-2a reduces exacerbation rate, MRI signs of disease activity and lymphocyte interferon gamma production in relapse-remitting multiple sclerosis . Neurol 44: 406-413 .

105.

Squillacote D , Martinez M , Sheremata W. (1996) Natural alpha interferon in multiple sclerosis - results of three preliminary series . J Int Med Res 24: 246-257 .

106.

Brod SA , Kerman RH , Nelson LD et al. (1997) Ingested IFN-alpha has biological effects in humans with relapsing-remitting multiple sclerosis . Multiple Sclerosis 3: 1-7 .

107.

Bongioanni MR , Durelli L , Ferrero B et al. (1996) Systemic high-dose recombinant-alpha-2a-interferon therapy modulates lymphokine production in multiple sclerosis . J Neurol Sci 143: 91-99 .

108.

Stone LA , Frank JA , Albert PS et al (1997) Characterization of MRI response to treatment with interferon beta- 1b: Contrast-enhancing MRI lesion frequency as a primary outcome measure . Neurol 49: 862-869 .

109.

Pliskin NH , Hamer DP , Goldstein DS et al. (1996) Improved delayed visual recognition test performance in multiple sclerosis patients receiving interferon beta- 1b . Neurol 47: 1463-1468 .

110.

Durelli L , Bongioanni MR , Ferrero B et al. (1996) Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: Disease activity resumes after stopping treatment . Neurol 47: 123-129 .

111.

Khan OA , Xia Q , Bever CT et al. (1996) Interferonbeta(1b) serum levels in multiple sclerosis patients following subcutaneous administration . Neurol 46: 1639-1643 .

112.

Miller A , Lanir N , Shapiro S et al. (1996) Immuno-regulatory effects of interferon-beta and interacting cytokines on human vascular endothelial cells. Implications for multiple sclerosis and other autoimmune diseases . J Neuroimmunol 64: 151-161 .

113.

Desimoni MG , Terreni L , Chiesa R et al , (1997) Interferon-gamma potentiates interleukin (IL)-6 and tumor necrosis factor-alpha but not IL-1-beta induced byendotoxininthebrain . Endocrinol 138: 5220-5226 .

114.

Brod SA , Marshall GD , Henninger EM et al. (1996) Interferon-beta(1b) treatment decreases tumor necrosis factor alpha and increases interleukin-6 production in multiple sclerosis . Neurol 46: 1633-1638 .

115.

Corsini E , Gelati M , Dufour A et al. (1997) Effects of beta-IFN-1b treatment in MS patients on adhesion between PBMNCs, HUVECs and MS-HBECs - an in vivo and in vitro study . J Neuroimmunol 79: 76-83 .

116.

Peitereit HF , Bamborschke S , Esse AD et al. (1997) Interferon gamma producing blood lymphocytes are decreased by interferon beta therapy in patients with multiple sclerosis . Multiple Sclerosis 3: 180-183 .

117.

Leppert D , Waubant E , Burk MR et al. (1996) Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis . Ann Neurol 40: 846-852 .

118.

Stuve O , Dooley NP , Uhm JH et al. (1996) Interferon beta-1b decreases the migration of T lymphocytes in vitro: Effects of matrix metalloproteinase-9 . Ann Neurol 40: 853-863 .

119.

Pette M , Pette DF , Muraro PA et al. (1997) Interferon-beta interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T-helper type I lymphocytes . Neurol 49: 385-392 .

120.

Stuve O , Chabot S , Jung SS et al. (1997) Chemokine-enhanced migration of human peripheral blood mono-nuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9 . J Neuroimmunol 80: 38-46 .

121.

Calabresi PA , Pelfrey CM , Tranquill LR et al. (1997) VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with beta interferon . Neurol 49: 1111-1116 .

122.

Rudick RA , Ransohoff RM , Peppler R et al. (1996) Interferon beta induces interleukin-10 expression. Relevance to multiple sclerosis . Ann Neurol 40: 618-627 .

123.

Nicoletti F , Patti F , Dimarco R et al. (1996) Circulating serum levels of IL-1RA in patients with relapsingremitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment . Cytokine 8: 395-400 .

124.

Calabresi PA , Tranquill LR , Dambrosia JM et al. (1997) Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon-beta-1b . Ann Neurol 41: 669-674 .

125.

IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group . (1996) Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b. Experience during the first three years . Neurol 47: 889-894 .

126.

Pachner AR. (1997) Anticytokine antibodies in beta interferon-treated MS patients and the need for testing. Plight of the practicing neurologist . Neurol 49: 647-650 .

127.

Fricker J. (1996) Developing drugs for multiple sclerosis. 348: 1022.

128.

Billiau A. (1995) Interferons in multiple sclerosis. Warnings from experiences . Neurol 45 (suppl. 6): S50-S53 .

129.

Neilley LK , Goodin DS , Goodkin DE et al. (1996) Side effect profile of interferon beta-1b in MS - results of an open-label trial . Neurol 46: 552-554 .

130.

Webster GF , Knobler RL , Lublin FD et al. (1996) Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis . J Am Acad Dermatol 34: 365-367 .

131.

Elgart GW , Sheremata W , Ahn YS. (1997) Cutaneous reactions to recombinant human interferon beta-1b - the clinical and histological spectrum . J Am Acad Dermatol 37: 553-558 .

132.

Feldmann R , Lowweiser H , Duschet P et al. (1997) Necrotizing cutaneous lesions caused by interferon beta injections in a patient with multiple sclerosis . Dermatol 195: 52-53 .

133.

Weinberg JM , Wolfe JT , Sood S et al. (1997) Cutaneous necrosis associated with recombinant interferon injection - report of three cases with interferon beta-1b and review of the literature . Acta Dermato-Venereologica 77: 146-148 .

134.

Mohr DC , Goodkin DE , Likosky W et al. (1997) Treatment of depression improves adherence to inter-feron beta-1b therapy for multiple sclerosis . Arch Neurol 54: 531-533 .

135.

Pakulski LA , Dimarco LM. (1997) Severe vaginal bleeding associated with recombinant interferon beta- 1b . Ann Pharmacotherap 31: 50-52 .

136.

Lublin FD , Whitaker JN , Eidelman BH et al. (1996) Management of patients receiving interferon beta-1b for multiple sclerosis - report of a consensus conference . Neurol 46: 12-18 .

137.

Schwartz CE , Coulthard-Morris L , Cole B et al. (1997) The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis . Arch Neurol 54: 1475-1480 .

138.

Rieckmann P , Weber F , Gunther A et al. (1996) The phosphodiesterase inhibitor pentoxifylline reduces early side effects of interferon-beta-1b treatment in patients with multiple sclerosis . Neurol 47: 604-604 .

139.

van Oosten BW , Rep MHG , Vanlier RAW et al. (1996) A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis . J Neuroimmunol 66: 49-55 .

140.

Rieckmann P , Weber F , Gunther A et al. (1996) Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis . J Neuroimmunol 64: 193-200 .

141.

Arnon R , Sela M , Teitelbaum D. (1996) New insights into the mechanism of action of copolymer-1 in experimental allergic encephalomyelitis and multiple sclerosis . JNeurol 243 (suppl. 1): S8-S13 .

142.

Bennun A , Mendel I , Bakimer R et al. (1996) The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic - effect of copolymer-1 on MOG-induced disease . JNeurol 243 (suppl. 1): S14-S22 .

143.

Lea AP , Goa KL. (1996) Copolymer-1 - A review of its pharmacological properties and therapeutic potential in multiple sclerosis . Clin Immunotherap 6: 319-331 .

144.

Korczyn AD , Nisipeanu P. (1996) Safety profile of copolymer-1 - analysis of cumulative experience in the United States and Israel . JNeurol 243 (suppl. 1): S23-S26 .

145.

Johnson KP. (1996) A review of the clinical efficacy profile of copolymer-1 - new US phase III trial data . J Neurol 243 (suppl. 1): S3-S7 .

146.

Fukaura H , Kent SC , Pietrusewicz MJ et al. (1996) Induction of circulating myelin basic protein and proteolipid-specific transforming growth factor-beta 1 secreting TH3 T cells by oral administration of myelin in multiple sclerosis patients . J Clin Invest 98: 70-77 .

147.

Racke MK , Critchfield JM , Quigley L et al. (1996) Intravenous antigen administration as a therapy for autoimmune demyelinating disease . Ann Neurol 39: 46-56 .

148.

Bai XF , Shi FD , Xiao BG et al. (1997) Nasal administration of myelin basic protein prevents relapsing experimental autoimmune encephalomyelitis in DA rats by activating regulatory cells expressing IL-4 and TGF-beta mRNA . J Neuroimmunol 80: 65-75 .

149.

Warren KG , Catz I , Wucherpfennig KW. (1997) Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85VVHFFKNIVTP96 in chronic progressive multiple sclerosis . J Neurol Sci 152: 31-38 .

150.

van Oosten VW , Lai M , Hodgkinson S et al. (1997) Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomised, double-blind, placebo-controlled, MR-monitored phase II trial . Neurol 49: 351-357 .

151.

Isaacs JD , Burrows N , Wing M et al. (1997) Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease . Clin Exp Immunol 110: 158-166 .

152.

Llewellynsmith N , Lai M , Miller DH et al. (1997) Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production A study of 29 multiple sclerosis patients entered into a clinical trial of CM-T412 . Neurol 48: 810-816 .

153.

Bourdette DN. (1996) A vaccine for multiple sclerosis is it a feasible option? CNS Drugs 5: 1-7 .

154.

Vandenbark AA , Chou YK , Whitman R et al. (1996) Treatment of multiple sclerosis with T-cell receptor peptides: Results of a double-blind pilot trial . Nature Med 2: 1109-1115 .

155.

Gold DP , Shroeder K , Golding A et al. (1997) T-cell receptor peptides as immunotherapy for autoimmune disease . Crit Revs Immunol 17: 507-510 .

156.

Beckett RP , Davidson AH , Drummond AH et al. (1996) Recent advances in matrix metalloproteinase inhibitor research . Drug Discovery Today 1: 16-26 .

157.

Webster HD. (1997) Growth factors and myelin regeneration in multiple sclerosis . Multiple Sclerosis 3: 113-120 .

158.

Duckers HJ , Vandokkum RP , Verhaagen J et al. (1996) Functional and neurophysiological evidence of the efficacy of trophic pharmacotherapy using an adrenocorticotrophic hormone analog in experimental allergic encephalomyelitis, an animal model of multiple sclerosis . Neurosci 71: 507-521 .

159.

Duckers HJ , Muller HJ , Verhaagen J et al. (1997) Longitudinal in vivo magnetic resonance imaging studies in experimental allergic encephalomyelitis - effect of a neurotrophic treatment on cortical lesion development . Neurosci 77: 1163-1173 .

160.

Delosmonteros AE , Zhao P , Huang C et al. (1997) Transplantation of CG4 oligodendrocyte progenitor cells in the myelin-deficient rat brain results in myelination of axons and enhanced oligodendroglial markers . J Neurosci Res 50: 872-887 .

161.

Leonard JP , Waldberger KE , Schaub RG et al. (1997) Regulation of the inflammatory response in animal models of multiple sclerosis by interleukin-12 . Crit Revs Immunol 17: 545-553 .